PR Newswire BiotechOriginal article
Interim Phase 2 Results from First-in-Class Combination of Invikafusp Alfa and TRODELVY® Selected for Oral Presentation at SITC 2026
Data ReadoutpositiveInvikafusp alfaTRODELVYPositive
AI Analysis
Summary
Interim Phase 2 results from the STARt-002 study evaluating the first-in-class combination of invikafusp alfa (Vβ6-selective T-cell agonist) and TRODELVY (TROP2-directed ADC) have been selected for oral presentation at SITC 2026.
Clinical Trial Data
Phase
2
Outcome Details
Interim Phase 2 results from STARt-002 combination study selected for oral presentation
Importance:6/10
Sentiment:
0.60
Phase 2Combination therapyT-cell agonistADCTROP2SITC 2026First-in-class
Related Companies
Read the original article
Published by PR Newswire Biotech on October 2, 2026 11:00 AM